What is semaglutide?
Semaglutide copies GLP-1, the fullness hormone your gut releases after eating — slowing digestion, quieting appetite, and steadying blood sugar. It's one of the most-studied molecules in modern metabolic medicine.
These articles cover it from every angle: mechanism, dosing, side effects, results measured in trials, and how compounded semaglutide differs from brand-name versions. It's prescription-only through Promise: a licensed provider reviews every request, and not everyone qualifies. If you're starting from zero, begin with the mechanism article — the rest makes more sense once the hormone story is clear.
96 articles on this topic
-
Semaglutide Pronunciation: How to Say It
Semaglutide is pronounced sem-a-GLOO-tide. The middle is easier once you know where the stress goes and why several related medicine names share the same ending.
-
503B Bulks List GLP-1: Still a Proposal
FDA proposes leaving three GLP-1 ingredients off the 503B bulks list. Comments closed July 30; patient-specific prescriptions follow separate rules.
-
Semaglutide Type 1 Diabetes: Guidance Has Limits
New 2026 guidance treats GLP-1 therapy as a possible obesity tool for some adults with type 1 diabetes, not as a replacement for insulin. The evidence is promising but small, and semaglutide is not approved to treat type 1 diabetes.
-
Novo Nordisk Lilly Lawsuit: What It Doesn't Decide
The fight is about how Zepbound ads frame a head-to-head trial after a higher Wegovy dose reached the market. It is not a court verdict on which medication is better for you.
-
Semaglutide News Update: September 2026
New child-trial results, heart-failure guidance, access changes and a June label update—what each means for a semaglutide prescription.
-
Semaglutide Before and After: An Honest Timeline
The first month is usually an adjustment period, month six is still part of the active curve, and a plateau often comes much later. Photos cannot show the treatment, timing, or follow-up behind a change.
-
FDA Telehealth Compounded Drugs: 5 Red Flags
FDA says telehealth sites must not present a compounded drug as a generic, a brand equivalent, or an agency-reviewed product. Here is what an honest prescription page should make clear.
-
Generic Semaglutide Exists—Just Not in the U.S.
Canada now has authorized semaglutide generics. The U.S. has only a tentative approval, while compounded semaglutide is another category altogether.
-
Orforglipron Is Approved: What Foundayo Changes
Orforglipron is now sold as Foundayo, a once-daily GLP-1 pill for weight management. It removes the fasting rules of oral semaglutide, but it does not replace every reason someone may choose an injection.
-
Retatrutide Early Access Is Real—and Very Limited
Retatrutide early access now exists through a narrow, doctor-led program. It is not a public prescription route, a sale, or an approval.
-
Semaglutide and Kidney Disease: The Full Picture
In the largest trial on the question, serious kidney events were 24% less common on semaglutide than on placebo. The other half of the story is dehydration — and the two keep getting confused.
-
Compounded Medication Recall: Check the Lot
A recall usually applies to one pharmacy, one preparation and specific lot numbers—not every compounded medication. Here is how to check a vial and reach the people responsible for it.
-
What Is Cagrilintide? The Amylin Half of CagriSema
Cagrilintide is an experimental copy of the appetite hormone amylin, and the other half of Novo Nordisk's CagriSema. It is not approved, it is not sold here, and a US decision is expected before the end of 2026.
-
Semaglutide and Tirzepatide Together? Usually No
Semaglutide and tirzepatide together are not a recommended combination. Both reach the same GLP-1 pathway; a switch should be planned as one treatment replacing the other, with timing and dose set by a prescriber.
-
GLP-1 Heart Failure Guidelines Changed in 2026
Europe's 2026 ESC guideline now says semaglutide or tirzepatide should be considered for a narrow group with symptomatic heart failure and obesity. It is an option for a cardiologist to weigh, not a direction to start either drug on your own.
-
Semaglutide for Children: What STEP Young Means
Semaglutide for children ages 6 to 11 has encouraging new trial results, but the news has not changed who can receive Wegovy under its current label. The evidence is promising, early, and best read with a pediatrician.
-
What Is Semaglutide Used For? A Plain Guide
Semaglutide has different jobs depending on the brand: blood sugar control, heart or kidney risk reduction, long-term weight management, or certain liver disease. Here is the plain list before a first visit.
-
Zepbound vs Wegovy: Two Drugs, Not Two Brands
They get compared like two versions of one medicine. They are not — different molecules, different makers, and different lists of what each one is cleared to treat.
-
No Shortcut: The Peptide FDA Approval Process
Mimrylo’s August 2026 approval is a useful look at the whole path: permission to begin human studies, three trial phases, a full application, manufacturing review, and a label limited to one use.
-
Retatrutide Lawsuit: It Is Still Investigational
Lilly sued six sellers in August, but the practical answer predates the cases: retatrutide remains investigational and no pharmacy can lawfully compound it for patients.
Page 2 of 5 · 96 articles